{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-014648","form_type":"8-K","ticker":"TELO","cik":"0001971532","company_name":"Telomir Pharmaceuticals, Inc.","filed_at":"2025-06-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.600303+00:00","generated_at":"2026-05-19T14:17:33.311540+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Telomir-1 shows dose-dependent reversal of Wilson's disease symptoms in animal model","bullets":["Up to 4-5x reduction in episodic tremor events; normalization of swim and exploratory behavior.","Approximately 50% reduction in copper accumulation in dry liver tissue.","ALT, AST, bilirubin restored to normal levels, indicating protection of liver function.","Significant improvement in liver and kidney histopathology scores to near-normal.","IND submission planned by year-end; human clinical trials targeted for H1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-014648","json":"https://secwatch.observer/filing/0001641172-25-014648.json","markdown":"https://secwatch.observer/filing/0001641172-25-014648.md","text":"https://secwatch.observer/filing/0001641172-25-014648.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971532/000164117225014648/0001641172-25-014648-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971532/000164117225014648/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T14:17:33.311540+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}